mRNA vaccines encoding influenza virus hemagglutinin (HA) elicits immunity in mice from influenza A virus challenge
PLOS ONE · 18.04.2024 · 19 (4) · e0297833
DOI: 10.1371/journal.pone.0297833 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 18.04.2024. Verfasst von Z Beau Reneer und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA, Unites States of America. Hauptthemen laut MEDLINE: Influenza Vaccines, Orthomyxoviridae Infections, Influenza A virus, Influenza, Human. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Immorna.
Abstract (Originalsprache)
Influenza viruses cause epidemics and can cause pandemics with substantial morbidity with some mortality every year. Seasonal influenza vaccines have incomplete effectiveness and elicit a narrow antibody response that often does not protect against mutations occurring in influenza viruses. Thus, various vaccine approaches have been investigated to improve safety and efficacy. Here, we evaluate an mRNA influenza vaccine encoding hemagglutinin (HA) proteins in a BALB/c mouse model. The results show that mRNA vaccination elicits neutralizing and serum antibodies to each influenza virus strain contained in the current quadrivalent vaccine that is designed to protect against four different influenza viruses including two influenza A viruses (IAV) and two influenza B (IBV), as well as several antigenically distinct influenza virus strains in both hemagglutination inhibition assay (HAI) and virus neutralization assays. The quadrivalent mRNA vaccines had antibody titers comparable to the antibodies elicited by the monovalent vaccines to each tested virus regardless of dosage following an mRNA booster vaccine. Mice vaccinated with mRNA encoding an H1 HA had decreased weight loss and decreased lung viral titers compared to mice not vaccinated with an mRNA encoding an H1 HA. Overall, this study demonstrates the efficacy of mRNA-based seasonal influenza vaccines are their potential to replace both the currently available split-inactivated, and live-attenuated seasonal influenza vaccines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA, Unites States of America.
- Immorna Biotherapeutics, Morrisville, NC, United States of America.
ORCID-Profile: Z Beau Reneer, Harrison C Bergeron, Ralph A Tripp
Förderung
- Immorna
Zitieren
APA
Reneer, Z. B., Bergeron, H. C., Reynolds, S., Thornhill-Wadolowski, E., Feng, L., Bugno, M., Truax, A. D., & Tripp, R. A. (2024). mRNA vaccines encoding influenza virus hemagglutinin (HA) elicits immunity in mice from influenza A virus challenge. PLOS ONE, 19(4), e0297833. https://doi.org/10.1371/journal.pone.0297833
Vancouver
Reneer ZB, Bergeron HC, Reynolds S, Thornhill-Wadolowski E, Feng L, Bugno M, et al. mRNA vaccines encoding influenza virus hemagglutinin (HA) elicits immunity in mice from influenza A virus challenge. PLOS ONE. 2024;19(4):e0297833. doi:10.1371/journal.pone.0297833
BibTeX
@article{Reneer2024,
author = {Reneer, Z Beau and Bergeron, Harrison C and Reynolds, Stephen and Thornhill-Wadolowski, Elena and Feng, Lan and Bugno, Marcin and Truax, Agnieszka D and Tripp, Ralph A},
title = {mRNA vaccines encoding influenza virus hemagglutinin (HA) elicits immunity in mice from influenza A virus challenge},
journal = {PLOS ONE},
year = {2024},
volume = {19},
number = {4},
pages = {e0297833},
doi = {10.1371/journal.pone.0297833}
}
EUVIMED